Ratings Fortrea Holdings Inc.

Equities

FTRE

US34965K1079

Real-time Estimate Cboe BZX Other stock markets 02:17:28 2024-05-10 pm EDT			5-day change	1st Jan Change
34.17 ^USD	-4.58%		-9.90%	-3.42%

Apr. 01	Fortrea Holdings Inc. Announces the Resignation of Betty Larson as from the Board, and All Board Committees	CI
Mar. 22	Baird Starts Fortrea Holdings With Neutral Rating, $43 Price Target	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company does not generate enough profits, which is an alarming weak point.
The group shows a rather high level of debt in proportion to its EBITDA.
The company is highly valued given the cash flows generated by its activity.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
FORTREA HOLDINGS INC.	-3.42%	3.2B	-
MODERNA, INC.	+18.42%	47.02B	B-
LONZA GROUP AG	+48.77%	41.86B	A
IQVIA HOLDINGS INC.	+0.67%	41.76B	B
CELLTRION, INC.	-4.27%	28.8B	C
ICON PUBLIC LIMITED COMPANY	+11.70%	26.05B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.82%	19.15B	B
BIO-TECHNE CORPORATION	+3.54%	12.55B	B+
MEDPACE HOLDINGS, INC.	+28.22%	12.34B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.55%	11.82B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes